Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease

Elliott J. Mufson, Milos D. Ikonomovic, Scot D. Styren, Scott E. Counts, Joanne Wuu, Sue Leurgans, David A. Bennett, Elizabeth J. Cochran, Steven T. DeKosky

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. Objective: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. Design and Main Outcome Measures: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD. Setting and Patients: Subjects were from the Rush Religious Orders Study and the University of Pittsburgh Alzheimer's Disease Research Center (Pittsburgh, Pa). Results: We found no changes in cortical or hippocampal NGF levels across groups; in MCI, levels did not correlate with an increase in choline acetyltransferase activity in these regions. Conclusion: Brain NGF levels appear sufficient to support the cholinergic plasticity changes seen in MCI and remain stable throughout the disease course.

Original languageEnglish
Pages (from-to)1143-1148
Number of pages6
JournalArchives of Neurology
Volume60
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Nerve Growth Factor
Alzheimer Disease
Brain
Choline O-Acetyltransferase
Cholinergic Agents
Cognitive Dysfunction
Alzheimer's Disease
Nerve
Mild Cognitive Impairment
Hippocampus
Enzyme-Linked Immunosorbent Assay
Outcome Assessment (Health Care)
Research
Proteins
Pittsburgh

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mufson, E. J., Ikonomovic, M. D., Styren, S. D., Counts, S. E., Wuu, J., Leurgans, S., ... DeKosky, S. T. (2003). Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Archives of Neurology, 60(8), 1143-1148. https://doi.org/10.1001/archneur.60.8.1143

Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. / Mufson, Elliott J.; Ikonomovic, Milos D.; Styren, Scot D.; Counts, Scott E.; Wuu, Joanne; Leurgans, Sue; Bennett, David A.; Cochran, Elizabeth J.; DeKosky, Steven T.

In: Archives of Neurology, Vol. 60, No. 8, 01.08.2003, p. 1143-1148.

Research output: Contribution to journalArticle

Mufson, EJ, Ikonomovic, MD, Styren, SD, Counts, SE, Wuu, J, Leurgans, S, Bennett, DA, Cochran, EJ & DeKosky, ST 2003, 'Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease', Archives of Neurology, vol. 60, no. 8, pp. 1143-1148. https://doi.org/10.1001/archneur.60.8.1143
Mufson, Elliott J. ; Ikonomovic, Milos D. ; Styren, Scot D. ; Counts, Scott E. ; Wuu, Joanne ; Leurgans, Sue ; Bennett, David A. ; Cochran, Elizabeth J. ; DeKosky, Steven T. / Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. In: Archives of Neurology. 2003 ; Vol. 60, No. 8. pp. 1143-1148.
@article{51d28ea48a934395ac2a0999b7b843e9,
title = "Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease",
abstract = "Background: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. Objective: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. Design and Main Outcome Measures: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD. Setting and Patients: Subjects were from the Rush Religious Orders Study and the University of Pittsburgh Alzheimer's Disease Research Center (Pittsburgh, Pa). Results: We found no changes in cortical or hippocampal NGF levels across groups; in MCI, levels did not correlate with an increase in choline acetyltransferase activity in these regions. Conclusion: Brain NGF levels appear sufficient to support the cholinergic plasticity changes seen in MCI and remain stable throughout the disease course.",
author = "Mufson, {Elliott J.} and Ikonomovic, {Milos D.} and Styren, {Scot D.} and Counts, {Scott E.} and Joanne Wuu and Sue Leurgans and Bennett, {David A.} and Cochran, {Elizabeth J.} and DeKosky, {Steven T.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1001/archneur.60.8.1143",
language = "English",
volume = "60",
pages = "1143--1148",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease

AU - Mufson, Elliott J.

AU - Ikonomovic, Milos D.

AU - Styren, Scot D.

AU - Counts, Scott E.

AU - Wuu, Joanne

AU - Leurgans, Sue

AU - Bennett, David A.

AU - Cochran, Elizabeth J.

AU - DeKosky, Steven T.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. Objective: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. Design and Main Outcome Measures: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD. Setting and Patients: Subjects were from the Rush Religious Orders Study and the University of Pittsburgh Alzheimer's Disease Research Center (Pittsburgh, Pa). Results: We found no changes in cortical or hippocampal NGF levels across groups; in MCI, levels did not correlate with an increase in choline acetyltransferase activity in these regions. Conclusion: Brain NGF levels appear sufficient to support the cholinergic plasticity changes seen in MCI and remain stable throughout the disease course.

AB - Background: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. Objective: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. Design and Main Outcome Measures: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD. Setting and Patients: Subjects were from the Rush Religious Orders Study and the University of Pittsburgh Alzheimer's Disease Research Center (Pittsburgh, Pa). Results: We found no changes in cortical or hippocampal NGF levels across groups; in MCI, levels did not correlate with an increase in choline acetyltransferase activity in these regions. Conclusion: Brain NGF levels appear sufficient to support the cholinergic plasticity changes seen in MCI and remain stable throughout the disease course.

UR - http://www.scopus.com/inward/record.url?scp=0043025510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043025510&partnerID=8YFLogxK

U2 - 10.1001/archneur.60.8.1143

DO - 10.1001/archneur.60.8.1143

M3 - Article

C2 - 12925373

AN - SCOPUS:0043025510

VL - 60

SP - 1143

EP - 1148

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 8

ER -